Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational cohort of lecanemab in early Alzheimer's disease
ChiCTR2500113750Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of lecanemab in Alzheimer's disease (AD) (2 arms), sponsored by Huashan Hospital. Primary endpoint: CDR-SB. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2500113750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113750.